Dermatomyositis and polymyositis (myositis) trials in Japan

In Japan 9 Also abroad 124

9 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Not yet taking people in Japan
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
Where
Aichi, Nagoya, Fukuoka, Kitakyushu, Fukushima, Fukushima, Hokkaido, Sapporo, Kanagawa, Kawasaki, Kanagawa, Yokohama, Kyoto, Kyoto, Miyagi, Sendai, Nara, Kashihara, Okayama, Okayama, Osaka, Suita, Tokyo, Bunkyo-ku, Tokyo, Ota-ku, Tokyo, Shinjuku-ku
Age
18 years and over
People
270 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07789015 · EU 2026-526365-24-00
Phase 1Taking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Bunkyō City, Kita-gun, Kitakyushu-shi, Kyoto, Nagasaki
Age
18 years to 70 years
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
Phase 3Enrolling by invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Where
Bunkyō City, Nagoya, Tokyo, Wakayama, Yamaguchi
Age
18 years and over
People
240 worldwide
Run by
argenx
See details and how to joinNCT05979441 · EU 2022-502851-79-00
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Where
Asahikawa-shi, Bunkyō City, Chiba, Fukuoka, Hiroshima, Iruma-Gun, Kawachinagano-shi, Kawasaki-shi, Nagoya, Okayama, Omura-shi, Sendai, Shinjuku-ku, Tachikawa-shi, Yotsukaido-shi
Age
18 years to 75 years
People
240 worldwide
Run by
AstraZeneca
See details and how to joinNCT06455449
Phase 3Taking people
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Where
Bunkyo-ku, Chuo-shi, Kawasaki, Kitakyushu-shi, Okayama, Ōtsu, Sendai, Shinjuku-ku, Ube, Wakayama
Age
18 years and over
People
318 worldwide
Run by
Pfizer
See details and how to joinNCT05895786 · EU 2022-502739-20-00
Phase 3Taking people
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Where
Bunkyo-ku
Age
18 years and over
People
211 worldwide
Run by
Pfizer
See details and how to joinNCT06698796 · EU 2024-514648-10-00
Phase 1Taking people
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Where
Bunkyo-ku, Hamamatsu, Himeji, Isehara, Kodaira, Okayama, Ōta-ku, Sakai, Sapporo, Sendai, Suita, Toyama
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00
Phase 1Enrolling by invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Where
Bunkyo-ku, Fukuoka, Hamamatsu, Himeji, Isehara, Kawachi-Nagano, Kodaira, Meguro-Ku, Okayama, Ōta-ku, Sakai, Sapporo, Sendai, Suita, Toyama
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06723106
Phase 1Taking people
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Where
Fukuoka, Hiroshima, Hokkaido
Age
18 years to 70 years
People
44 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00